Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, has today announced closing of its initial public offering of 16,103,572 American Depositary Shares (“ADSs”), each representing an ordinary share at an initial public offering price of $14.00 per share. The gross proceeds from the offering were $225.5 million before deducting underwriting commissions and estimated offering expenses.
Based upon research arising from the groups of Prof. Bobby Gaspar and Prof. Adrian Thrasher at the UCL Institute of Child Health, Orchard Therapeutics has been supported by UCLTF since its first investment round in 2016. The spinout marks the first of UCLTF’s early stage investments to file for IPO.
Read more from the story here: Orchard Therapeutics